Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01889368 · ClinicalTrials.gov registry record · NA
Effect of a Grape Seed Extract (GSE) on Insulin Resistance
A NA study, sponsored by University of California, Davis.
- Completed
- Registry status
- NA
- Development phase
- 19
- Enrollment target
NCT01889368 is a NA study that has completed, run by University of California, Davis. The registered enrollment target is 19 participants.
The verdict
NCT01889368, a NA study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
Study Summary
In people with the metabolic syndrome, the investigators hypothesize that administration of a single 300 mg dose of a grape seed extract (GSE) will reduce insulin resistance (how well cells in the body can take up and use glucose), oxidative stress, and the amount of oxidized LDL in the blood during a 24 hour period. These measurements will be assessed at hourly intervals during the 24 hour study day protocol. Additionally, the investigators hypothesize that daily administration of 300 mg of GSE for 30 days will decrease baseline insulin resistance, oxidative stress, and the level of oxidized LDL in the blood.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Grape Seed Extract
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2012-11 |
| Est. Completion | 2015-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01889368
The ClinicalTrials.gov registry entry for NCT01889368 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01889368 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01889368 about?
NCT01889368 is a clinical study titled "Effect of a Grape Seed Extract (GSE) on Insulin Resistance". In people with the metabolic syndrome, the investigators hypothesize that administration of a single 300 mg dose of a grape seed extract (GSE) will reduce insulin resistance (how well cells in the body can take up and use glucose), oxidative stress, and the amount of oxidized LDL in the blood during...
What is the current status of trial NCT01889368?
This trial is currently completed. It is a NA study. The enrollment target is 19 participants. The study started on 2012-11. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01889368?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Grape Seed Extract (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01889368?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.